CA 15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 5257-5261

  Begum, Mumtaz ^a   Karim, Sajjad ^b   Malik, Arif ^a   Khurshid, Rukhshan ^a   Asif, Muhammad ^c   Salim, Asmat ^d   Nagra, Saeed Ahmed ^e   Zaheer, Ahmad ^f   Iqbal, Zafar ^g   Abuzenadah, Adel Mohammed ^b   Alqahtani, Mohammed Hussain ^b   Rasool, Mahmood ^b  

^a UNIVERSITY OF LAHORE   (Pakistan)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c BALOCHISTAN UNIVERSITY OF INFORMATION TECHNOLOGY   (Pakistan)

^d UNIVERSITY OF KARACHI   (Pakistan)

^e UNIVERSITY OF THE PUNJAB   (Pakistan)

^f National Institute for Biotechnology   (Pakistan)

^g KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

Author keywords

Breast cancer; CA 15 3; ELISA; Estrogen; Mucin1; Pakistan; Transmembrane protein

Indexed keywords

EID: 84874011498     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.5257     Document Type: Article

References (45)

1. Ahmed F, Mahmud S, Hatcher J, Khan SM (2006). Breast cancer risk factor knowledge among nurses in teaching hospitals of Karachi, Pakistan: a cross-sectional study. BMC Nur, 5, 6-8.
2. Babu GR, Samari G, Cohen SP (2011). Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev, 12, 1647-55.
3. Bairoch A, Apweiler R (1997). The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Nucleic Acids Res, 25, 31-6.
4. Balducci L, Beghe C, Parker M, Chausmer A (2005). Prognostic evaluation in geriatric oncology: problems and perspectives. Archives of Gerontology and Geriatrics, 3, 31-41.
5. Barnes BB, Chang Claude J, Flesch Janys D, et al (2009). Cancer risk factors associated with insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status. Cancer Causes Control, 20, 1985-96.
6. Baruch A, Hartmann M, Yoeli M, Adereth Y, et al (1999). The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer Res, 59, 1552-61.
7. Baum M, Denton S (1981). Breast cancer: the facts. Oxford University Press, 15-40.
8. Beenken SW, Grizzle WE, Crowe DR, et al (2001). Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg, 233, 630-8.
9. Cancer Research UK, (2012). UK Breast Cancer Incidence Statistics. Retrieved 11.9.2012, from http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/
10. Dumitrescu RG (2005). Understanding breast cancer risk-where do we stand in 2005?. J Cell Mol Med, 9, 208-21.
11. Fan NJ, Gao CF, Zhao G, Wang XL, Liu QY (2012). Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis. Diagn Pathol, 20, 45.
12. Gendler SJ (2001). MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia, 21, 339-53.
13. Gierach GL, Ichikawa L, Kerlikowske K, et al (2012). Relationship between mammographic density and breast cancer death in the breast cancer surveillance consortium. J Natl Cancer Inst, 104, 1218-27.
14. Hindle WH (1990). Breast disease for gynaecology: epidemiology-risk factors. Appleton and Lange Norwalk, 30.
15. Howe GR, Freidenrich CM, Jaim M, Miller AB (1991). A cohort study of fat intake and risk of breast cancer. J Natl Cancer Inst, 83, 336-40.
16. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
17. Jiang XP, Yang DC, Elliot RL, Head JF (2000). Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125-results in immune and clinical responses in breast cancer patients. Cancer Biother. Radiopharm, 15, 495-505.
18. Kakugawa Y, Minami Y, Tateno H, Inoue H, Fujiya T (2007). Relation of serum levels of estrogen and dehydroepiandrosterone sulfate to hormone receptor status among postmenopausal women with breast cancer. Breast Cancer, 14, 269-76.
19. Khan A, Newman LA (2004). Diagnosis and management of ductal carcinoma in situ. Curr Treat Options Oncol, 5, 131-44.
20. Korde LA, Calzone KA, Zujewski J (2004). Assessing breast cancer risk: genetic factors are not the whole story. Postgrad Med, 116, 19-20.
21. Kufe DW (2012). MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. doi: 10.1038/onc.2012.158. [Epub ahead of print].
22. Liu C, Zhang H, Shuang C, et al (2010). Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications. Med Oncol, 27, 747-52.
23. Miller AB, Berrino F, Hill M, Riobali PE, Wahramdrof J (1994). Diet in the aetiology of cancer: a review. Eur J Cancer, 30, 207-20.
24. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004). Endogenous estrogen, androgen and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst, 96, 1856-8.
25. Molina R, Auge JM, Farrus B, et al (2010). Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem, 56, 1148-57.
26. Mukherjee P, Ginardi AR, Tinder TL, Sterner CJ, Gendler SJ (2001). MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. Clin Cancer Res, 7, 848-55.
27. Muttlin C (1984). Diet and the epidemiology of breast cancer. Cancer, 53, 605-11.
28. Norum LF, Nilsson O, Nustad K (2001). Automated immunofluorometric assay for MUC. Tumour Biol, 22, 169-75.
29. Perkins EA, Small BJ, Balducci L, et al (2007). Individual differences in well-being in older breast cancer survivors. Crit Rev Oncol/Hematol, 62, 74-83
30. Parry S, Silverman HS, McDermott K, Willis A (2001). Identification of MUC1 proteolytic cleavage sites in vivo, Biochem. Biophys. Res Commun, 283, 715-20.
31. Rahn JJ, Chow JW, Horne GJ, et al (2005). MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis, 22, 475-83.
32. Rakha EA, Boyce RW, Abd D, et al (2005). Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol, 18, 1295-304.
33. Sandri MT, Salvatici M, Botteri E, et al (2012). Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Br Cancer Res Treat, 132, 317-26.
34. Sattin RW, Rubin GL, Webster LA, et al (1985). Family history and the risk of breast cancer. Breast Cancer Res, 253, 230-41.
35. Saxena N, Hartman M, Bhoo-Pathy N, et al (2012). Breast cancer in South East Asia: comparison of presentation and outcome between a middle income and a high income country. W J Surg, 36, 2838-46.
36. Segal-Eiras A, Croce MV (1997). Breast cancer associated mucin: a review. Allergol Immunopathol (Madr), 25, 176-81.
37. Tang Y, Wang L, Zhang P, et al (2010). Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol, 17, 1903-8.
38. Truant S, Bruyneel E, Gouyer V, et al (2003). Requirement of both mucins and proteoglycans in cell-cell dissociation and invasiveness of colon carcinoma HT-29 cells. Int J Cancer, 104, 683-94.
39. Tsuda H (1994). Accumulation of gene alterations and progression of breast cancer. Gan To Kagaku Ryoho, 21, 172-7.
40. VanLith ML, Kohlgraf KG, Sivinski CL, Tempero RM (2002). Hollingsworth MA.MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses. Int Immunol, 14, 873-82.
41. Verkooijen HM, Chappuis PO, Rapiti E, et al (2006). Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Bri J Cancer, 94, 231-8.
42. Vrieling A, Buck K, Heinz J, et al (2012). Pre-diagnostic alcohol consumption and postmenopausal breast cancer survival: a prospective patient cohort study. Br Cancer Res Treat, 136, 195-207.
43. Voet D, Voet JG, Pratt CW (1999). Fundamentals of Biochemistry. John Wiley and Sons, Inc, New York.
44. Wei X, Xu H, Kufe D (2006). MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell, 21, 295-305.
45. Zhang HM, Xuan LX, Gao JD, Zhang BN, Zhao P (2009). Clinical characteristics comparison between triple-negative and non-triple-negative breast cancer. Zhonghua Wai Ke Za Zhi, 47, 506-10.